Learn about the latest trends and activities through our blog posts.
According to a December 1, 2021 press release, Representatives Carter (R-GA) and Gonzalez (D-TX) have reintroduced the Drug Price Transparency in Medicaid Act. The legislation “would limit the power of pharmacy benefit managers (PBMs) to artificially spike Medicaid drug prices. The Drug Price Transparency in Medicaid Act bans the use of spread pricing by middlemen (PBMs) in Medicaid managed care. PBMs drive up prescription drug costs without adding any value to the consumer.”
Read MoreThis week the 8th Circuit issued a decision in the case of Pharmaceutical Care Management Association v. Wehbi, which supported North Dakota’s legislative actions to regulate pharmacy benefit managers (PBMs). PCMA v. Wehbi is the first case at the federal appellate level since the landmark Rutledge v. PCMA decision last year that upheld Arkansas law also regulating PBMs.
Read MoreOral arguments have been scheduled for September 1, 2021 at 2:00 PM CST for PCMA v. Wehbi. Earlier this year, the U.S. Supreme Court vacated this 8th Circuit case formerly known as Wilke v. PCMA.
Read MoreVia a recently released a press release describing how a group of bipartisan Senators including Joe Manchin (D-WV), Joni Ernst (R-IA), Jeanne Shaheen (D-NH), and Jerry Moran (R-KS) have introduced the bipartisan Protecting Rural Telehealth Access Act to make current telehealth flexibilities permanent.
Read MoreOn September 13, 2020, the Trump Administration released a new Executive Order (EO) targeting drug pricing.
Read MoreRon Lanton; Principal of Lanton Law addresses the National Association of Specialty Pharmacy on emerging specialty issues.
Read MoreWe have been providing occasion updates through our blog on the U.S. Supreme Court case of Rutledge v. PCMA, whose outcome could have wide ranging policy and legal ramifications on pharmacy and pharmacy benefit managers.
Read MoreAlana Hippensteele; Editor, MA of Pharmacy Times interviewed Ron Lanton to discuss how COVID-19 may lead to expansion of practice laws for pharmacists across the country.
Read MoreWe have a new article in the American College of Apothecaries (ACA) titled “What’s Next for DIR Policy?”
Read MoreRon Lanton III, Esq., discusses the specialty pharmacist's role in educating patients about biosimilars and biologics.
Read MoreWatch Ron Lanton give Specialty Pharmacy Times his insight on the Prescription Drug Price Relief Act.
Read More
